Characterization and relevance of physicochemical interactions among components of a novel multiparticulate formulation for colonic delivery

International Journal of Pharmaceutics

Volumn 341, Issue 1-2, 2007, Pages 143-151

  Singh, Brahma N ^a   Kim, Kwon H ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Azathioprine; Drug polymer interactions; Incompatibility; Ionotropic gelation; Polysaccharide beads

Indexed keywords

AZATHIOPRINE; CALCIUM ION; EUDRAGIT; GELLAN; METAL ION; POLYMER;

ARTICLE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY DIFFRACTION;

ACETYLATION; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; CALCIUM; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; COLON; CRYSTALLOGRAPHY, X-RAY; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GASTROINTESTINAL AGENTS; GELS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; POLYMETHACRYLIC ACIDS; POLYSACCHARIDES, BACTERIAL; POWDER DIFFRACTION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 34447629717     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.04.005     Document Type: Article

References (29)

1. Aso Y., and Yoshioka S. Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid dispersions as measured by 13C-NMR spin lattice relaxation time. J. Pharm. Sci. 95 (2006) 318-325
2. Baker R. Controlled Release of Biologically Active Agents (1987), Wiley, New York
3. Chandrasekaran R., and Thailambal V.G. The influence of calcium ions, acetate and l-glycerate groups on the gellan double-helix. Carbohydr. Polym. 12 (1990) 431-442
4. 4, Hg (II) and MeHg (II). Can. J. Appl. Spectr. 39 (1994) 81-86
5. Chifotides H.T., Katsaros N., and Pneumatikakis G. Complexes of azathioprine, a biologically active mercaptopurine derivative, with Pt (II), Pd (II), Rh (III), Ru (III) and Ag (I). J. Inorg. Biochem. 56 (1994) 249-264
6. Cilurzo F., Minghetti P., Selmin F., Casiraghi A., and Montanari L. Polymethacrylate salts as new low-swellable mucoadhesive materials. J. Control Rel. 88 (2003) 43-53
7. Dash A.K., Khin-Khin A., and Suryanarayanan R. X-ray powder diffractometric method for quantitation of crystalline drug in microparticulate systems. I. Microspheres. J. Pharm. Sci. 91 (2002) 983-990
8. Dubler E. Metal complexes of sulfur-containing purine derivatives. In: Sigel A., and Sigel H. (Eds). Metal Ions in Biological Systems vol. 32 (1996), Marcel Dekker Inc., New York 301-338
9. Gu L., Strickley R.G., Chi L.-H., and Chowan Z.T. Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation. Pharm. Res. 7 (1990) 379-383
10. Hsiue G.H., Liao C.M., and Lin S.Y. Effect of drug-polymer interaction on the release characteristics of methacrylic acid copolymer microcapsules containing theophylline. Artif. Org. 22 (1998) 651-656
11. Jansen P.J., Oren P.L., Kemp C.A., Maple S.R., and Baertschi S.W. Characterization of impurities formed by interactions of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate. J. Pharm. Sci. 87 (1998) 81-85
12. Jay A.J., Colquhoun I.J., Ridout M.J., Brownsey G.J., Morris V.J., Fialho A.M., Leitão J.H., and Sá-Correia I. Analysis of structure and function of gellans with different substitution patterns. Carbohydr. Polym. 35 (1998) 179-188
13. Katzhendler I., Azoury R., and Friedman M. Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets based on hydroxypropyl methylcellulose. J. Control Rel. 54 (1998) 69-85
14. Konno H., and Taylor L.S. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci. 95 (2006) 2692-2705
15. Lorenzo-Lamosa M.L., Remuñán-López C., Vila-Jato J.L., and Alonso M.J. Design of microencapsulated chitosan microspheres for colonic drug delivery. J. Control Rel. 52 (1998) 109-118
16. Miyazaki T., Yoshioka S., Aso Y., and Kojima S. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J. Pharm. Sci. 93 (2004) 2710-2717
17. Miyazaki T., Yoshioka S., and Aso Y. Physical stability of amorphous acetanilide derivatives improved by polymer excipients. Chem. Pharm. Bull. 54 (2006) 1207-1210
18. Miyoshi E., Takaya T., and Nishinari K. Rheological and thermal studies of gel-sol transition in gellan gum aqueous solutions. Carbohydr. Polym. 30 (1996) 109-119
19. Puttipipatkhachorn S., Nunthanid J., Yamamoto K., and Peck G.E. Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. J. Control Rel. 75 (2001) 143-153
20. ® S-100 (INFO 7.3/E).
21. Sandborn W.J. Azathioprine: state of the art in inflammatory bowel disease. Scand. J. Gastroenterol. 33 (1998) 92-99
22. Singh S., Gulati M., and Gupta R.L. Complexation behavior of azathioprine with metal ions. Int. J. Pharm. 68 (1991) 105-110
23. Singh B.N., Trombetta L.D., and Kim K.H. Biodegradation behavior of gellan gum in simulated colonic media. Pharm. Dev. Technol. 9 (2004) 399-407
24. Singh B.N., and Kim K.H. Effects of divalent cations on drug encapsulation efficiency of deacylated gellan gum. J. Microencapsul. 22 (2005) 761-771
25. Singh B.N. Modified-release solid formulations for colonic delivery. Recent Pat. Drug Deliv. Formul. 1 (2007) 53-63
26. Takka S. Propranolol hydrochloride-anionic polymer binding interaction. Farmaco 58 (2003) 1051-1056
27. Tanaka M., Asahi Y., Masuda S., and Ota T. Binding position of azathioprine with bovine serum albumin determined by measuring nuclear magnetic resonance relaxation time. Chem. Pharm. Bull. 39 (1991) 2771-2774
28. Wong T.W., Chan L.W., Kho S.B., and Heng P.W.S. Design of controlled-release solid dosage forms of alginate and chitosan using microwave. J. Control Rel. 84 (2002) 99-114
29. Zhang G.G.Z., Law D., Schmitt E.A., and Qiu Y. Phase transformation considerations during process development and manufacture of solid dosage forms. Adv. Drug Deliv. Rev. 56 (2004) 371-390